Corrona Japan Rheumatoid Arthritis (RA) Registry
Not Applicable
Recruiting
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000021394
- Lead Sponsor
- CorEvitas, LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2600
Inclusion Criteria
Not provided
Exclusion Criteria
NA
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to prospectively study the comparative effectiveness and comparative safety of approved therapies for RA in a Japanese cohort of patients treated by rheumatologists. Specifically the effectiveness and safety of newer classes and dosages of DMARDs (e.g. higher dose MTX, non-TNF biologics, and JAK inhibitors) will be compared with anti-TNF biologics.
- Secondary Outcome Measures
Name Time Method Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, and current treatment practices.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie rheumatoid arthritis progression in the Corrona Japan RA Registry?
How does the Corrona Japan RA Registry compare disease-modifying antirheumatic drug effectiveness with standard-of-care treatments?
Which biomarkers are associated with treatment response prediction in rheumatoid arthritis patients from the Corrona Japan RA Registry?
What adverse events are reported in the Corrona Japan RA Registry and how are they managed in clinical practice?
Are there related compounds or combination therapies being explored for rheumatoid arthritis in parallel to the Corrona Japan RA Registry study?